Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FH-006 + adebrelimab + bevacizumab + cisplatin + carboplatin
- Development stage
- Unknown
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy is an investigational regimen developed by Jiangsu HengRui Medicine for the treatment of lung cancer. It consists of FH-006, a recombinant humanized monoclonal antibody targeting the PVRIG (PVR-related immunoglobulin domain-containing protein) immune checkpoint; adebrelimab (SHR-1316), a monoclonal antibody targeting the PD-L1 (Programmed death-ligand 1) checkpoint; BP102, a bevacizumab biosimilar that inhibits VEGF (Vascular Endothelial Growth Factor) to suppress tumor angiogenesis; and the platinum-based chemotherapeutic agents cisplatin and carboplatin, which act as DNA alkylators to induce cytotoxic effects. By combining multiple immune checkpoint inhibitors with anti-angiogenic therapy and traditional chemotherapy, this regimen aims to maximize anti-tumor responses and overcome resistance mechanisms in lung cancer patients.
- Brand names
- Airuika
- Other names
- FH-006 + SHR-1316 + BP102 + cisplatin + carboplatin
02
Targets
B7-H3DNAEGFR (Epidermal growth factor receptor)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)
Beyond the preview
Go deeper on FH-006 + adebrelimab + bevacizumab + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FH-006 + adebrelimab + bevacizumab + cisplatin + carboplatin.